* Pharvaris NV PHVS.OQ PHVS.O is expected to report
results on October 7 (estimated).
* Refinitiv's mean analyst estimate for Pharvaris NV is for a
loss of 45 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Pharvaris NV is
$48, about 63.2% above its last closing price of $17.64.
* Previous quarterly performance (using preferred earnings
measure in euros).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Jun. 30 2021 -0.39 -0.42 -0.94 Missed -122
Mar. 31 2021 -0.34 -0.38 -0.66 Missed -72.5
Dec. 31 2020 -1.14 -1.14 -2.18 Missed -90.7
This summary was machine generated October 7 at 12:51 GMT. All
figures in euros unless otherwise stated